Page 336 - பிராங்க்ஃபர்ட் ஸ்டாக் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investment breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns Media Links Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M One of the most successful inventors and entrepreneurs who masterminded the unprecedented success of Qiagen N.V. from a start-up to a 10 billion market cap enterprise has taken the decision to refocus his activities on BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB). BrainRepair UG has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year. Metin Colpan’s patented invention has become a standard method recommended by the World Health Organization (WHO) and is used by researchers all over the world, changing the way they can access, purify and understand genetic data in DNA and RNA. The European Patent Office states “…The tireless work of Ge

Nordrhein westfalenThierry bernardMetin colpanArne jensenEuropean patent officeWorld health organizationEuropean commissionEuropean medicines agencyFrankfurt stock exchangeUniversity bochumRuhr university bochumAdvisory boardNasdaq first northOrphan drug designationEuropean medicinesPrime standard